You are here

Press Release Archive

 
December 22, 2015 - Pfizer Invites Public To View And Listen To Webcast Of February 2 Conference Call With Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, February 2, 2016. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2015 Performance Report, to be issued that morning.

 
December 22, 2015 - Merck KGaA, Darmstadt, Germany and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelumab

Merck KGaA, Darmstadt, Germany and Pfizer today announced the opening of trial sites for an international Phase III study of avelumab*

 
December 14, 2015 - Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the Guggenheim 3rd Annual Boston Healthcare Conference on Tuesday, December 15, 2015 at 12:00 p.m. Eastern Standard Time.

 
December 14, 2015 - Pfizer Declares First-Quarter 2016 Dividend

The board of directors of Pfizer Inc. today declared a 30-cent first-quarter 2016 dividend on the company’s common stock, payable March 2, 2016, to shareholders of record at the close of business on February 5, 2016. Pfizer increased the dividend by approximately 7 percent, to 30 cents from 28 cents per share.

 
December 10, 2015 - Pfizer Announces FDA Acceptance of IBRANCE® (palbociclib) Supplemental New Drug Application with Priority Review in HR+, HER2- Metastatic Breast Cancer

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted Priority Review for a supplemental New Drug Application (sNDA) for Pfizer’s breast cancer medication, IBRANCE® (palbociclib).

 
December 9, 2015 - Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Two Phase III Studies of Investigational Immunotherapy Avelumab in Advanced Gastric and Gastro-esophageal Junction Cancers

Merck KGaA, Darmstadt, Germany, and Pfizer today announced the initiation of two Phase III studies of avelumab*, an investigational, fully human anti-PD-L1 IgG1 monoclonal antibody, in treating advanced or metastatic gastric/gastro-esophageal junction (GEJ) cancers, which are aggressive cancers with poor survival rates.

 
December 8, 2015 - Pfizer Awards More Than $4 Million in Grants to Further Clinical Research in Advanced Breast Cancer for 2015

Pfizer Inc. today announced the first-ever recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards.

 
December 7, 2015 - Pfizer Receives U.S. FDA Approval of New QuilliChew ER™ (methylphenidate hydrochloride) extended-release chewable tablets CII

Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved QuilliChew ER chewable tablets.

 
December 1, 2015 - Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Mikael Dolsten, President, Worldwide Research and Development, at the 27th Annual Piper Jaffray Healthcare Conference on Wednesday, December 2, 2015 at 9:00 a.m. Eastern Standard Time.

 
November 25, 2015 - Pfizer Reports Top-Line Results from a Phase 3 Study of LYRICA® (pregabalin) Capsules CV in Adults with Post-Traumatic Peripheral Neuropathic Pain

Pfizer Inc. (NYSE:PFE) announced today top-line results of a Phase 3 study evaluating the efficacy and safety of LYRICA® (pregabalin) Capsules CV in adults with chronic post-traumatic peripheral neuropathic pain. The study did not meet its primary efficacy endpoint.

 
November 25, 2015 - Merck KGaA, Darmstadt, Germany, and Pfizer Receive Positive Opinion for Orphan Drug Designation for Avelumab in Merkel Cell Carcinoma from EMA Committee for Orphan Medicinal Products

Merck KGaA, Darmstadt, Germany, and Pfizer today announced that the European Medicines Agency (EMA)’s Committee for Orphan Medicinal Products (COMP) has issued a positive opinion for Orphan Drug designation (ODD) for avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, pending an official decision by the European Commission (EC), expected in December. 

 
November 25, 2015 - Pfizer Receives European Approval to Expand Use of XALKORI® (crizotinib) to First-Line Treatment of Adults with ALK-Positive Advanced Non-Small Cell Lung Cancer

Pfizer Inc. (NYSE:PFE) today announced that the European Commission has approved a label update to expand use of XALKORI® (crizotinib) to first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). 

 
November 23, 2015 - Pfizer and Allergan to Combine

Pfizer Inc.

 
November 18, 2015 - Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma

Merck KGaA, Darmstadt, Germany, and Pfizer today announced that the US Food and Drug Administration (FDA) has granted avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Breakthrough Therapy designation for the treatment of patients with metastatic Merkel cell carcinoma (MCC) who have progressed after at least one previous chemotherapy regimen.

 
November 5, 2015 - Pfizer Expands its Patient Assistance Program, Doubling the Income Eligibility Limit to Benefit Even More Patients Taking Pfizer Medicines

In response to the ongoing challenges patients face in paying their out-of-pocket costs for their prescription medicines, Pfizer announced today that it will immediately double the allowable income level for its patient assistance program, so that even more patients in need could be eligible to receive their Pfizer medicines for free.

Pages

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

 

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

pdf

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.

Current Stock Price

.
.
%Change . 52 Wk. High .
Day High . 52 Wk. Low .
Day Low . Mkt. Cap(Mil) .
Open .
Prev Close . Symbol .
Vol. . Exchange .

Online Pfizer Press Kit

Our press kit provides information that might help you write stories or simply find out more about Pfizer.